Frequency and duration of remission after isolated limb perfusion for melanoma.

OBJECTIVE To examine the frequency and duration of complete remission for locally recurrent and metastatic limb melanoma after isolated limb perfusion (ILP) with cytotoxic agents. DESIGN A case series of 114 consecutive therapeutic ILPs performed between April 1984 and April 1994 and a review of previously published studies. SETTING A tertiary referral center for melanoma treatment, located at a university teaching hospital. RESULTS Of 111 assessable ILPs, 81 (73%) resulted in complete limb tumor remission and 14 (13%) resulted in partial remission (defined as a reduction in size of tumor deposits by > 50%). Complete remission was maintained in 37 (46%) of the 81 cases without any further treatment (median follow-up, 33 months; range, 8-112 months). Of the other 44 cases, disease subsequently recurred in the perfused limb (median time to recurrence, 9.5 months; range, 2-65 months). In 19 of these cases, however, the limb was again disease free at last follow-up after local surgery (12 cases) or a repeat ILP (7 cases). Overall, complete locoregional control was achieved after 50% of assessable ILPs, and a long-term disease-free state in the limb was achieved, with or without further treatment, in 56 (69%) of the 81 cases in which an initial complete remission occurred. For 743 therapeutic ILPs undertaken in 12 series previously reported in the literature, an initial complete remission was reported in 50% of these cases and partial remission in 32%. CONCLUSION Therapeutic ILP is an effective form of treatment for patients with recurrent and metastatic limb melanoma, achieving short- and long-term results that are superior to those achievable by any other form of treatment currently used.

[1]  A. Eggermont,et al.  Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. , 1996, Journal of the American College of Surgeons.

[2]  G. Balderson,et al.  Hyperthermic isolated limb perfusion for malignant melanoma: Response and survival , 1995, World journal of surgery.

[3]  R. Cavaliere,et al.  Hyperthermic antiblastic perfusion in the treatment of stage IIIA-IIIAB melanoma patients. Comparison of two experiences. , 1994, Melanoma research.

[4]  P. Kam,et al.  Hyperthermic isolated limb perfusion in the treatment of melanoma : technical aspects , 1994 .

[5]  A. Hart,et al.  Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. , 1994, Surgery.

[6]  R. Mirimanoff,et al.  Regional therapy of melanoma. , 1993, European journal of cancer.

[7]  J. Thompson,et al.  Isolated limb perfusion for melanoma: Effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs , 1992, World journal of surgery.

[8]  J. Zee,et al.  Results of a double perfusion schedule using high-dose hyperthermia and melphalan sequentially for recurrent melanoma of the limbs: a pilot study , 1992 .

[9]  D. Coit Hyperthermic isolation limb perfusion for malignant melanoma: a review. , 1992, Cancer investigation.

[10]  J. Thomas,et al.  Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb , 1990, The British journal of surgery.

[11]  S. Carlini,et al.  Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion , 1989, Cancer.

[12]  B. Kroon,et al.  Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. , 1988, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[13]  D. Morton,et al.  Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. , 1985, American journal of surgery.

[14]  P. Jönsson,et al.  Results of regional hyperthermic perfusion for primary and recurrent melanomas of the extremities. , 1983, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[15]  A. Verhest,et al.  Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan. , 1983, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[16]  E. V. van Slooten,et al.  Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. , 1982, European journal of cancer & clinical oncology.

[17]  G. Westbury,et al.  Isolated limb perfusion for malignant melanoma. , 1980, The Practitioner.

[18]  G. Simert,et al.  The effect of regional perfusion treatment on recurrent melanoma of the extremities. , 1977, Acta chirurgica Scandinavica.

[19]  R. F. Ryan,et al.  Chemotherapy of Cancer: Regional Perfusion Utilizing an Extracorporeal Circuit , 1958, Annals of surgery.